Lupin Pharma

Lupin, Granules India recall 971,000 diabetes drug bottles from US market

As per the USFDA, the companies are recalling the product due to deviation from the current good manufacturing practices

Unichem, Lupin recall high blood pressure drugs from US over quality issues

The specified batch, which is being recalled, has been manufactured at Unichem's Goa-based facility

Margin improvement holds key for Lupin with US sales likely to soften

Go ahead for inhaler launch in the US and resolution of plant compliance issues are other triggers

Lupin gains 3% as Vizag API facility receives EIR from USFDA

Brokerage firm Prabhudas Lilladher has upgraded Lupin's stock to 'Buy' from earlier 'Reduce' with target price of Rs 978

Lupin pharma receives EIR from USFDA for Mandideep Unit II facility

The inspection at the facility was carried out by the US Food and Drug Administration between November 26, 2018

Lupin extends gain into sixth session as Mandideep unit gets EIR from USFDA

The stock of the drug maker has rallied 47 per cent in the past six trading days, and was quoting close to its 52-week high level of Rs 882

Clearance from US drug regulator key for Lupin to sustain stock gains

The recent gains came on Monday after the company received the USFDA approval for its Nagpur facility

Lupin gets EIR from USFDA for its manufacturing plant in Nagpur

The company's shares surged 4.14% to Rs 820.40 after they received the inspection report (EIR) from the US drug regulator

Coronavirus outbreak: Quick USFDA approvals for asthma drug makers

Cipla gets nod for drug from USFDA earlier than expected; Lupin in fray

Sun Pharma stock sheds 15% on price fixing concerns, slow portfolio ramp-up

The near-term worry for the company is the ongoing investigation by the US Department of Justice related to price fixing and cartelisation by generic companies

Lupin falls 3% as USFDA issues 5 observations for Vizag facility

The United States Food and Drug Administration (USFDA) carried out the inspection of the company's Vizag API manufacturing facility between January 13, 2020 and January 17, 2020.

Lupin faces regulatory challenges; high costs hit profit margins in Q3

High costs have hit Q3 margins, while multiple one-offs have impacted firm's bottom line

Lupin gets 2 observations from USFDA after Nagpur facility inspection

The USFDA issues observations by means of Form 483 notifying a company's management of objectionable conditions at the facility inspected

Lupin gets USFDA approval to market generic skin ointment Desoximetasone

The Mumbai-based company's product is the generic version of Taro Pharmaceuticals Inc's Topicort Ointment.

Lupin's partner Concord gets USFDA nod to market generic Myfortic tablet

The product is a generic version of Novartis Pharmaceuticals Corporation's Myfortic delayed-release tablets in the same strengths, it added

Lupin's arm Nanomi BV completes stake divestment in Kyowa Pharma

Last month, Lupin's board had approved the stake sale in Kyowa

Top stock recommendations by Anand Rathi: Buy Lupin, Zensar Tech

Trading calls by Jay Anand Thakkar, CMT -Assistant Vice President - Equity Research, Anand Rathi Shares and Stock Brokers

Lupin sells Japan arm to Unison for Rs 3,702 cr, exits generic business

The company will now focus on specialty products in Japan; it is open to inorganic opportunities, especially in India

Lupin's prophylaxis and chronic asthma treatment drug gets USFDA nod

The medicine is indicated for prophylaxis and treatment of chronic asthma in adults and children 12 years of age and older, it added.

Lupin posts net loss of Rs 127 cr, US market holds key to firm's rerating

While pricing pressure in the US generics market remains in low single digits, large product approvals are crucial to boost sales